AzTrials
AzTrials

Graves' OphthalmopathyNCT00174057

The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy

An observational study of Graves' Ophthalmopathy, run by National Taiwan University Hospital at 1 site in Taiwan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The exact mechanism of the pathogenesis of Graves' ophthalmopathy is still unknown. Histopathologically, extraocular muscle inflammation and orbital fat inflammation are two prominent changes. Read more about this study

Who is it for?
Ages 20 years and older
Conditions the study is for
Graves' Ophthalmopathy
How many people
50 participants
Where
1 siteTaiwan
Study dates
Aug 2005to Jul 2006
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

None listed.

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country.

Taiwan1 site, 1 recruiting
  • Shu Lang Liao

    Taipei

    Shu Lang Liao, MD, 886-2-23123456 ext. 5729, lang89@ha.mc.ntu.edu.tw

    Luke L-K Lin, PhD

    Recruiting

Other trials in Taiwan

About this study

The exact mechanism of the pathogenesis of Graves' ophthalmopathy is still unknown. Histopathologically, extraocular muscle inflammation and orbital fat inflammation are two prominent changes. In the past year, we had investigated the morphological features of the Müller muscle in patients with thyroid lid retraction using the special stain and immunohistochemistry. In our findings, the smooth muscle cells, in the diseased group, were replaced by variable adipose and fibrosis tissues.

In recent years, TSHR, has been verified to express in orbital connective tissue and extra-ocular muscle. From functional studies and an increase in adipogenesis in cultured fibroblasts with expression of TSHR protein, the role not only the target but effector cells in orbital fibroblasts were validated. Quantitative RT-PCR may help to differentiate whether a less extent of expression at the end stage or low protein amount to be detected.

Read more

In recent years, the diverse phenotypes of orbital fibroblasts, with regard to expression of Thy-1 protein or not, had been reported from several studies, the investigators believed heterogeneity in orbital fibroblast may determine the clinical presentation of Graves'ophthalmopathy. We also are curious to know if the phenotypic heterogeneity of the fibroblasts in the ocular adnexal and orbital tissues correlates to distinct morphological features of adipogenesis and fibrosis.

Moreover, increased CD40 expression in skin fibroblasts were noted from patients with systemic sclerosis. Expression of IGF-I and IGF-IR seemed to be up-regulated in processes of several fibrotic diseases. A nuclear transcription factor, PPAR-γ, has been verified to have a close relationship with adipogenesis. We hypothesize that some immunological processes involve the ocular adnexal and orbital tissues, which result in various ophthalmological manifestations.

The purpose of this study is to investigate the different stage of the ocular adnexal and orbital tissues to identify the pathogenesis of Graves' ophthalmopathy by frozen sections with Immunohistochemistry, mRNA expression of TSH receptor, PPAR-γ, IGF-1R, and IGF-1 and different cytokines using quantitative RT-PCR and flow cytometry at the acute and stable stage in GO.

Read the detailed description

The exact mechanism of the pathogenesis of Graves' ophthalmopathy (GO) is still unknown. Histopathologically, extraocular muscle inflammation due to lymphoid infiltration, edema and interstitial fibrosis, and increased glycosaminoglycan deposition and orbital fat inflammation are two prominent changes. There are various manifestations including ocular adnexal tissues inflammation, proptosis, lid retraction, extraocular movement limitation and compressive optic neuropathy. In the past year, we had investigated the morphological features of the Müller muscle in patients with thyroid lid retraction using the special stain and immunohistochemistry in formalin-fixed paraffin-embbeded (FFPE) sections. In our findings, the smooth muscle cells, in the diseased group, were replaced by variable adipose and fibrosis tissues. Two distinct features in the disease group seem to be notable for further investigation.

In recent years, TSHR, a putative autoantigen, has been verified to express in orbital connective tissue and extra-ocular muscle. In addition, they were further demonstrated to express on the surface of cultured orbital fibroblasts and orbital adipose tissue, in patients with GO in several laboratories. From functional studies and an increase in adipogenesis in cultured fibroblasts with expression of TSHR protein, the role not only the target but effector cells in orbital fibroblasts were validated7. We used immunohistochemistry to verify the existence of TSHR on the fibroblasts within the Müller muscle, and the positive staining is manifested in only18 % of patients. It may due to a less extent of expression at the end stage. We are very curious to know if there any difference on the expression of TSHR between orbital specimens from patients with acute and those with stable stage. Quantitative RT-PCR may help to differentiate whether a less extent of expression at the end stage or low protein amount to be detected.

In recent years, the diverse phenotypes of orbital fibroblasts, with regard to expression of Thy-1 protein or not, had been reported from several studies, the investigators believed heterogeneity in orbital fibroblast may determine the clinical presentation of Graves' ophthalmopathy. We also are curious to know if the phenotypic heterogeneity of the fibroblasts in the ocular adnexal and orbital tissues correlates to distinct morphological features of adipogenesis and fibrosis. In addition, systemic or local pro-inflammatory cytokines may contribute to turn on and turn off the expression of different roles of the fibroblasts.

Moreover, increased CD40 expression in skin fibroblasts were noted from patients with systemic sclerosis. Expression of IGF-I and IGF-IR seemed to be up-regulated in processes of several fibrotic diseases. A nuclear transcription factor, PPAR-γ, has been verified to have a close relationship with adipogenesis. In our previous study, the smooth muscle cells, in the diseased Mullers' muscle, were replaced by variable adipose and fibrosis tissues. The increased adipose and fibrosis tissue ex vivo of the Müller' muscle may result from over-action of some biochemical markers in the fibroblasts infiltrating around muscle cells. We hypothesize that some immunological processes involve the ocular adnexal and orbital tissues, which result in various ophthalmological manifestations.

The purpose of this study is to investigate the different stage ( acute or stable stage) of the ocular adnexal and orbital tissues ( including orbital fat, extraocular muscles, orbicularis muscles and eyelid fat) to identify and validate the pathogenesis of Graves ophthalmopathy by frozen sections of the ocular adnexal and orbital tissues with Immunohistochemistry (IHA) (Thy-1 and PPARγ), mRNA expression of TSH receptor, PPAR-γ, IGF-1R, and IGF-1 and different cytokines (IL-1β, IL-4, IL-6, IL-8) using quantitative RT-PCR and flow cytometry at the acute and stable stage in GO.

Keywords
Graves' ophthalmopathy, real time PCR, cytokines, Tsh receptor
Medical subject headings
Graves Ophthalmopathy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Sep 2005 (estimated)
  2. Study startAug 2005
  3. Study completionJul 2006

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Other
Enrolment
50 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00174057
Sponsor's protocol ID
9461700644
Status last verified
Jun 2005
First submitted
13 Sep 2005
Last updated
15 Sep 2005
Results posted
No

Questions about this trial

What is this clinical trial studying?

An observational study of Graves' Ophthalmopathy, run by National Taiwan University Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Sep 2005. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2005.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in